苏州瑞博生物技术股份有限公司

我们的治疗领域

• 

  心血管、代谢及肾脏疾病

  Cardiometabolic disease are one of the leading causes of death worldwide, accounting for 32% of global deaths. Cardiometabolic disease refers to a group of disorders that involve the functioning of the heart and blood vessels, as well as metabolic disturbances, including hypertension, diabetes, dyslipidemia, and obesity, etc. These diseases are interconnected and can lead to atherosclerosis, target organ damage, and various complications, increasing the risk of cardiovascular events. Medical treatment and appropriate lifestyle changes can effectively prevent and improve the prognosis of Cardiometabolic disease.

  
• 

  肝脏疾病

  The liver is one of the most important organs in the body. Some liver diseases, such as viral hepatitis and fatty liver disease, can lead to cellular damage and fat accumulation in the liver, impairing its normal functions. Cirrhosis of the liver is a late disease state with significant loss of functioning liver cells, inflammation and shrinkage of the liver tissue. It is associated with structural remodeling and hardening of the liver, damaging its metabolic and regenerative capacities, and may lead to end-stage liver disease or liver cancer. We are dedicated to protecting the health of every liver disease patient and ensuring their safety.

  
• 

  其他大量医疗需求的治疗领域

  There are over 7,000 known rare diseases worldwide, with less than 1% being treatable. Due to the diagnosis and treatment of rare diseases pose significant challenges, and patients often have no available treatments, with some medications being prohibitively expensive. We are committed to developing innovative drugs for rare diseases, bringing hope to patients.